Resolution of inflammation and induction of immune tolerance are essential to stabilize immune homeostasis and to limit the occurrence of exacerbated inflammatory and autoimmune conditions. Multiple mechanisms act together to ensure the re-establishment of immune homeostasis and maintenance of tolerance. The identification of endogenous factors that regulate these processes is crucial for the development of new therapies for inflammatory/autoimmune conditions. Neuropeptides produced during an ongoing inflammatory response emerged as endogenous anti-inflammatory agents that participate in processes leading to the resolution of inflammation and maintenance of tolerance. Anti-inflammatory neuropeptides and hormones such as vasoactive intestinal peptide, urocortin, adrenomedullin, melanocyte stimulating hormone, ghrelin, and cortistatin have beneficial effects in a variety of experimental inflammatory and autoimmune models. Their therapeutic effect has been attributed to their capacity to downregulate innate immunity, to inhibit antigen-specific T H 1-driven responses, and to generate regulatory T cells. Finally, some of these neuropeptides have been identified as mediators of innate defense acting as natural antimicrobial peptides. Here we present the research findings in the neuropeptide immunoregulatory field, and examine possible therapies based on anti-inflammatory neuropeptides and hormones as a new pharmacologic platform.
Introduction
Elimination of pathogens through the activation of the immune system followed by re-establishment of immune homeostasis requires multiple interactions between various types of immune cells and between the immune and neuroendocrine systems. Among neuroendocrine mediators, neuropeptides, expressed, and released primarily but not exclusively by the nervous system, have profound effects on the immune response.
Recent developments in the field of immunoregulatory neuropeptides led to the special named series ''Neuropeptide Regulation of Immunity" published in Brain Behavior and Immunity. The studies published in this series encompass the anatomical localization of peptidergic nerve fibers in close proximity to lymphocytes (Shibata et al., 2008) , the potent anti-inflammatory activity of neuropeptides/hormones such as vasoactive intestinal peptide (VIP), endomorphin 1 and 2, and alpha-melanocyte stimulating hormone (a-MSH) (Gonzalez-Rey and Delgado, 2008; Gutierrez-Cañas et al., 2008; Taylor and Kitaichi, 2008; Colombo et al., 2008; Anton et al., 2008) , the regulation of neuropeptide receptor expression in immune cells (Murthy et al., 2008; Vomhof-DeKrey et al., 2008; Vomhof-DeKrey and Dorsam, 2008) , and the dependence of immune parameters such as thymus involution and T lymphocyte output, in addition to growth hormone expression, on signalling through ghrelin receptors (Yang et al., 2008) .
The review concluding this special named series reports on various mechanisms involved in the activity of a growing number of anti-inflammatory neuropeptides and discusses their possible use as new therapeutic agents.
Following the elimination of pathogens, inflammation has to be resolved to re-establish homeostasis. The consequences of uncontrolled activation of innate and adaptive immunity and of sustained production of inflammatory mediators are deleterious for the host. Acute inflammation can lead to chronic inflammation, scarring and tissue destruction, and eventually to organ failure (Goodnow, 2007) .
Although there is substantial information on the molecular basis of the initiation of an inflammatory process, we know much less about the mechanisms that resolve inflammation. Recently, it has been recognized that inflammatory responses are self-controlled by endogenous anti-inflammatory mediators secreted by the host innate immune system during an ongoing inflammatory process, and that the ability to control an inflammatory state depends on the local balance between pro-and anti-inflammatory factors (Nathan, 2002) .
